LYTIX BIOPHARMA ASA LYTIX Innsideinformasjon

Lytix Biopharma ASA: Private placement and retail offer via Nordnet successfully completed

18. November 2026 kl. 01:43

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS NOT A PROSPECTUS AND DOES NOT CONSTITUTE A PUBLIC OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 18 November 2026. Reference is made to the stock exchange announcement published by Lytix Biopharma ASA ("Lytix Biopharma" or the "Company") on 17 November 2026 regarding a contemplated private placement raising NOK 60-80 million in gross proceeds (the "Private Placement") and an offering of new shares directed at retail investors in Norway to raise gross proceeds of up to the NOK equivalent of EUR 1 million, facilitated via Nordnet Bank AB ("Nordnet") and made through its facilities (the "Retail Offering").

The Company is pleased to announce that the Private Placement and Retail Offering have been successfully completed and raised aggregate gross proceeds of NOK 80 million.

The Company's board of directors (the "Board") has resolved to allocate 9,335,133 Offer Shares at a price per share of NOK 8.0 (the "Offer Price") in the Private Placement, raising gross proceeds of NOK 74,681,064. The Private Placement received strong support from the Company's largest shareholders, who pre-committed to subscribe for Offer Shares in the Private Placement, with Saturn Invest AS and HIFO Invest AS being allocated a total of 3,286,535 Offer Shares, TAJ Holding AS being allocated 2,411,535 Offer Shares, Jakob Hatteland Holding AS being allocated 1,411,535 Offer Shares and Per Strand Eiendom AS being allocated 1,036,535 Offer Shares. Further, the Company's CEO, Øystein Rekdal, and CFO, Gjest Breistein, have each been allocated 12,500 Offer Shares in the Private Placement. Additionally, the Company's Board has resolved to allocate 664,867 Offer Shares at the Offer Price in the Retail Offering, raising gross proceeds of NOK 5,318,936. Notifications of allocations in the Private Placement and the Retail Offering are expected to be distributed to applicants on 18 November 2026.

Over the past years, Lytix Biopharma has developed into a more mature and de-risked clinical-stage company. Ruxotemitide has shown strong clinical results across several Phase II studies in multiple skin cancer indications. The Company's key near-term value driver is the potential of ruxotemitide in neoadjuvant melanoma, treatment before surgery. It covers a large patient group with strong commercial prospects, and current treatment options leave substantial room for improvement. The Phase II NeoLIPA study (ruxotemitide plus pembrolizumab) recently met its primary endpoint, and a more detailed data set will be presented as a late-breaking abstract at ESMO IO in London mid-December 2026. The capital raise aims to strengthen the clinical case for ruxotemitide through the ALETTA study, an investigator-led Phase II study in neoadjuvant melanoma in combination with ipilimumab and nivolumab, and to fund preparations for a planned registrational Phase III study in neoadjuvant melanoma.

The net proceeds from the Private Placement and the Retail Offering will be used for Phase III readiness activities for ruxotemitide in neoadjuvant melanoma, the Company's share of the costs of the ALETTA study, advancing LTX-401 towards Phase I, and general corporate purposes. The Phase III study itself will require additional financing and/or a partner.

"We are grateful for the strong support from our largest shareholders and pleased to welcome new investors, including the retail investors who participated through Nordnet," said Øystein Rekdal, CEO of Lytix Biopharma. "The proceeds allow us to prepare for a registrational Phase III study of ruxotemitide in neoadjuvant melanoma and to advance LTX-401 towards the clinic. We look forward to the presentation of updated NeoLIPA data at ESMO IO in London in December."

Settlement of the Offer Shares in the Private Placement is expected to take place on 20 November 2026. Settlement of the Offer Shares in the Retail Offering will take place on the same date, in accordance with the procedures communicated by Nordnet through its website.

The Offer Shares (including the shares allocated in the Retail Offering) will, other than for the Share Lenders (as defined below), be settled on a delivery-versus-payment ("DVP") basis with existing and unencumbered shares in the Company that are already listed on Euronext Growth Oslo, to be borrowed from Jakob Hatteland Holding AS, Saturn Invest AS and TAJ Holding AS (in their capacity as such, the "Share Lenders") by the Manager pursuant to a share lending agreement entered into between the Manager, the Company and the Share Lenders (the "Share Lending Agreement"). The share loan, including Offer Shares allocated to the Share Lenders, will be settled with new shares (equal to the number of Offer Shares) in the Company to be issued by the Board pursuant to the authorisation granted by the Company's extraordinary general meeting on 26 January 2026 (the "Board Authorisation").

Offer Shares allocated to investors other than the Share Lenders will be tradeable from notification of allocation, expected on or about 18 November 2026. Offer Shares allocated to, and borrowed from, the Share Lenders will be delivered and become tradeable following registration of the share capital increase in the Norwegian Register of Business Enterprises ("NRBE").

Following registration of the share capital increase pertaining to the issuance of the Offer Shares in the Private Placement and Retail Offering, the Company's share capital will be NOK 8,690,000.50 divided on 86,900,005 shares, each with a par value of NOK 0.10.

Conditions for completion

Completion of the Private Placement is subject to the Share Lending Agreement remaining unmodified and in full force and effect.

Lock-up

Customary lock-up agreements have been entered into with the Company for 90 days, and members of management and the Board for 180 days.

Equal treatment considerations and subsequent offering

The Board has considered the structure of the Private Placement and Retail Offering in light of the equal treatment obligations under the Norwegian Public Limited Liability Companies Act and Rule Book II for companies listed on Euronext Growth Oslo, and is of the opinion that the Private Placement and Retail Offering are in compliance with these requirements. By structuring the transaction as a Private Placement, with a parallel Retail Offering pursuant to applicable exemptions from prospectus filing requirements, the Company has been successful in raising capital in an efficient manner. Furthermore, the number of Offer Shares issued in connection with the Private Placement and Retail Offering implies that the dilution of existing shareholders is limited, approximately 12%. On this basis and based on an assessment of the current equity markets, the Board has concluded that the Private Placement and Retail Offering are in the best interest of the Company and its shareholders. As a consequence of the chosen transaction structure, the shareholders' preferential rights to subscribe for the Offer Shares have been set aside.

As part of the Board's assessment set out above, and in order to further limit the dilutive effect of the Private Placement and the Retail Offering, the Board has resolved to carry out a subsequent offering of new shares at the Offer Price, raising gross proceeds of up to NOK 15 million (the "Subsequent Offering"). The Subsequent Offering will, subject to applicable securities laws, be directed towards existing shareholders in the Company as of 17 November 2026 (as registered in the VPS two trading days thereafter) who (i) were not included in the pre-sounding phase of the Private Placement, (ii) were not allocated Offer Shares in the Private Placement or the Retail Offering, and (iii) are not resident in a jurisdiction where such offering would be unlawful or would (in jurisdictions other than Norway) require any prospectus, filing, registration or similar action. The Subsequent Offering is further subject to (i) the completion of the Private Placement and the Retail Offering, (ii) the resolution by the Board to issue the new shares pursuant to the Board Authorisation, (iii) the publication of a national prospectus pertaining to the Subsequent Offering, and (iv) the prevailing market price of the Company's shares together with the corresponding trading volume following the Private Placement. The Company may, in consultation with the Manager, decide that the Subsequent Offering will not be carried out if the Company's shares trade at or below the subscription price in the Subsequent Offering at sufficient volumes.

Advisors

DNB Carnegie, a part of DNB Bank ASA, is acting as sole bookrunner (the "Manager").

Advokatfirmaet Thommessen AS is acting as legal advisor to the Company.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This stock exchange announcement was published by Gjest Breistein on 18 November 2026 at the time set out in this notice on behalf of the Company.

For further information, please contact:

Gjest Breistein, CFO gjest.breistein@lytixbiopharma.com +47 952 60 512

About Lytix Biopharma Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to effectively prime durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as monotherapy and in combination therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker LYTIX.

Important information: This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to "qualified institutional buyers" as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The "Prospectus Regulation" means Regulation (EU) 2017/1129, as amended (together with any applicable implementing measures) in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

The issue, subscription or purchase of shares or other financial instruments in the Company is subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Manager assumes any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. Any forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Such assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not make any guarantee that the assumptions underlying any forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on any forward-looking statements in this announcement. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.

This announcement is made by, and is the responsibility of, the Company. The Manager is acting exclusively for the Company and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, or for advice in relation to the contents of this announcement or any of the matters referred to herein. Neither the Manager nor any of its affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. This announcement is an advertisement and is not a prospectus for the purposes of the Prospectus Regulation as implemented in any Member State.